MKM Partners analyst Eric Handler maintains Hasbro (NASDAQ:HAS) with a Buy and lowers the price target from $118 to $105.
Amicus Therapeutics Provides EU Regulatory Update For AT-GAA
Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for